RA Capital Reduces Vor Biopharma Stake by $10.2M, Now Owns 19.9%
Summary
RA Capital Management, a major institutional investor and director, reported selling approximately $10.2 million worth of Vor Biopharma shares, reducing its beneficial ownership to 19.9%.
Key Events
-
Significant Share Sales by Institutional Investor
RA Capital Healthcare Fund, L.P. sold a total of 620,133 shares of Vor Biopharma common stock between April 8 and April 10, 2026, for an aggregate value of approximately $10.2 million.
-
Reduced Ownership Stake
Following these transactions, RA Capital Management, L.P. and its affiliates beneficially own 12,554,642 shares, representing 19.9% of the company's outstanding common stock.
-
Continued Disposition Pattern
These sales continue a pattern of dispositions by RA Capital, as evidenced by recent Form 4 filings, suggesting a strategic reduction in their investment.
Analysis
RA Capital Management, a significant institutional investor with board representation through Peter Kolchinsky, has continued to reduce its stake in Vor Biopharma. This Schedule 13D/A reports sales of approximately $10.2 million in common stock between April 8 and April 10, 2026. These transactions, which overlap with a concurrently filed Form 4, follow previous dispositions by RA Capital, indicating a consistent reduction in their position. This continued selling by a major holder and director, especially against the backdrop of the company's recently reported $696.0 million net loss and negative equity for 2025, could signal a lack of confidence or a need for liquidity, potentially creating an overhang on the stock. Investors should monitor future filings for further changes in RA Capital's ownership.
At the time of this filing, VOR was trading at $15.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $755.7M. The 52-week trading range was $2.62 to $65.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.